Halozyme's revenue momentum is accelerating sharply, with 2026Q2 revenue up 47.7% year-over-year to $481.0M and gross margin expanding to 83.5%, driven by its asset-light royalty model and strong partner demand.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 47.7% year-over-year in 2026Q2, with gross margin expanding to 83.5% and operating margin reaching 59.8%, though a one-time charge in 2025Q4 caused a net loss of $141.6M.
Halozyme Therapeutics, Inc. (HALO) stock is actively traded with vital information available for investors.
HALO stock provides real-time price data, charts, key statistics, and news for informed decisions.
MarketBeat offers HALO stock analysis, price targets, earnings estimates, and short interest data.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $2.39+3.9% vs $2.30 | $493M+0.3% vs $492M |
Q3 2026 Aug 6, 2026 | $2.28+27.4% vs $1.79 | $481M+19.6% vs $402M |
Q2 2026 May 11, 2026 | $1.60+3.2% vs $1.55 | $377M+5.0% vs $359M |
Q1 2026 Feb 17, 2026 | -$0.24-111.2% vs $2.15 | $452M+3.7% vs $436M |
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.
SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026. "Based on our analysis of CMS's final rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.
Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication does not include patients with oropharyngeal squamous cell carcinoma that is HPV-associated.
Benchmark HALO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Halozyme Therapeutics, Inc. (HALO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $58.16 | $8.19B | -26.06 | 23258.15% | -47.79% | -60.05% | — | |
| $69.57 | $17.49B | 20.10 | 6.98% | 35.45% | 45.54% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
Halozyme Therapeutics, Inc. (HALO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Halozyme Therapeutics, Inc. (HALO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 2, 2026·SEC
May 11, 2026·SEC
Get notified when HALO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Halozyme Therapeutics, Inc. (HALO) stock FAQ — growth, dividends, profitability & financials explained
Halozyme Therapeutics, Inc. (HALO) reported $1.80B in revenue over the trailing twelve months. Revenue was $1.40B in fiscal year 2025. That is 5657631% more than the $0.0M of fiscal year 2001.
Halozyme Therapeutics, Inc. (HALO) grew revenue by 45.0% over the trailing twelve months, compared with the twelve months before.
Yes. Halozyme Therapeutics, Inc. (HALO) earned $485.4M in net income over the trailing twelve months (a 26.9% net margin).
Halozyme Therapeutics, Inc. (HALO) had a return on equity (ROE) of 544.3% over the trailing twelve months. That is well above the market's typical 10-15%.
Halozyme Therapeutics, Inc. (HALO) generated $885.9M in free cash flow over the trailing twelve months.
